STP1 is a fixed dose combination of PDE4/3 inhibitor (ibudilast) and NKCC1 antagonist (bumetanide) shown to be a top drug match for a subgroup of patients with autism spectrum disorder (ASD) called phenotype 1.
STP1 has completed phase 1b trials showing strong safety and tolerability, improvements in brain function for executive function and memory and improved autism severity scores. STP1 is being progressed into Phase 2 trials in 2025.
STP2, or SFX-01, is a stabilized synthetic form of sulforaphane for which STALICLA has acquired the rights for neurodevelopment disorders worldwide from TheraCryf (formerly known as Evgen Pharma) in October 2022.
STP2 is being advanced as a precision medicine treatment candidate for a subgroup of patients with ASD called Phenotype 2. Phase 1 data is currently being evaluated to support further clinical development into phase 2 trials.
STP7 (Mavoglurant) is the most clinically advanced negative allosteric modulator of the glutamate receptor 5 (mGluR5 NAM) (licensed from Novartis).
It has been administered to for up to 2 years in over 1800 patients in Phase 2 trials and STALICLA will advance it in two formulations, 100mg MR for a subgroup of patients with ASD (Phen7) and at the higher 200mg MR for Phase 3 trials in cocaine use disorder (CUD) in collaboration with National Institute on Drug Abuse (NIDA).